{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:14:46Z","timestamp":1787501686522,"version":"build-2736575974"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":582,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T00:00:00Z","timestamp":1716422400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Bussan Animal Health Co., Ltd"},{"name":"the Center for Diversity, Equity & Inclusion, Azabu University"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Zonisamide (ZNS) is a newer generation antiseizure medication (ASM) used to treat epilepsy in dogs and cats. However, scientific and clinical information, particularly regarding monotherapy, is limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the antiseizure efficacy and tolerability of ZNS monotherapy in dogs with newly diagnosed idiopathic epilepsy (IE).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Animals<\/jats:title>\n                    <jats:p>Study included 56 client-owned dogs newly diagnosed with IE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a prospective multicenter, open-label, uncontrolled study. All dogs were ASM-na\u00efve and had \u22652 seizures within 12\u2009weeks. Dogs were administered 2.7-14.4\u2009mg\/kg ZNS PO q12h and followed up for \u226512\u2009weeks. Data from the 12-week maintenance treatment period were compared with those from the 4- to 12-week pretreatment period for efficacy evaluation. Data from the entire ZNS administration period were used to assess tolerability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Fifty-six dogs were included in our study. Of the dogs, 53 were assessed for efficacy; 40 (76%) had a\u2009\u2265\u200950% reduction in seizure frequency, and 29 (55%) achieved seizure freedom. For 90% of the dogs with \u226550% reduction in seizure frequency, the mean ZNS dose was 4.8 (range, 2.7-8.6) mg\/kg q12h and the mean trough plasma ZNS concentration was 18.9 (range, 8.0-48.0) \u03bcg\/mL. In 7 of the 56 dogs (13%), reduced activity, decreased appetite, vomiting, hindlimb weakness, soft stools, or constipation was observed, albeit mild and temporary. Laboratory tests revealed no relevant changes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Clinical Importance<\/jats:title>\n                    <jats:p>Our study suggests that ZNS monotherapy is effective and well-tolerated in dogs with newly diagnosed IE.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jvim.17108","type":"journal-article","created":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T09:49:27Z","timestamp":1716457767000},"page":"2228-2236","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Clinical efficacy and tolerability of zonisamide monotherapy in dogs with newly diagnosed idiopathic epilepsy: Prospective open-label uncontrolled multicenter trial"],"prefix":"10.1093","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6560-070X","authenticated-orcid":false,"given":"Miyoko","family":"Saito","sequence":"first","affiliation":[{"name":"Laboratory of Small Animal Surgery (Neurology), School of Veterinary Medicine, Azabu University , Sagamihara,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinori","family":"Nomura","sequence":"additional","affiliation":[{"name":"Bussan Animal Health Co, Ltd Department of Product Development, , Osaka,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7554-9108","authenticated-orcid":false,"given":"Daisuke","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Laboratory of Veterinary Clinical Neurology, Graduate School of Veterinary Medicine, Nippon Veterinary and Life Science University , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoyuki","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Watanabe Animal Hospital , Shizuoka,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Uchida","sequence":"additional","affiliation":[{"name":"AC-plaza Kariya Animal Hospital , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiichi","family":"Okuno","sequence":"additional","affiliation":[{"name":"Animal Clinic Kobayashi , Saitama,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Nakai","sequence":"additional","affiliation":[{"name":"Bussan Animal Health Co, Ltd Department of Product Development, , Osaka,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Orito","sequence":"additional","affiliation":[{"name":"Laboratory of Physiology II, School of Veterinary Medicine, Azabu University , Sagamihara,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,7,1]]},"reference":[{"key":"2026020304081986300_jvim17108-bib-0001","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1021\/jm00188a011","article-title":"Studies on 3-substituted 1,2-benzisoxazole derivatives. 6. Syntheses of 3-(sulfamoylmethyl)-1,2-benzisoxazole derivatives and their anticonvulsant activities","volume":"22","author":"Uno","year":"1979","journal-title":"J Med Chem"},{"key":"2026020304081986300_jvim17108-bib-0002","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0006-8993(87)90168-5","article-title":"Zonisamide enhances slow sodium inactivation in Myxicola","volume":"413","author":"Schauf","year":"1987","journal-title":"Brain Res"},{"key":"2026020304081986300_jvim17108-bib-0003","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0920-1211(92)90087-A","article-title":"Zonisamide blocks T-type calcium channel in rat cultured cerebral neurons","volume":"12","author":"Suzuki","year":"1992","journal-title":"Epilepsy Res"},{"key":"2026020304081986300_jvim17108-bib-0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0169-328X(03)00183-9","article-title":"Effect of zonisamide on molecular regulation of glutamate and GABA transporter proteins during epileptogenesis in rats with hippocampal seizures","volume":"116","author":"Ueda","year":"2003","journal-title":"Mol Brain Res"},{"key":"2026020304081986300_jvim17108-bib-0005","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.eplepsyres.2005.10.001","article-title":"Effects of zonisamide on neurotransmitter exocytosis associated with ryanodine receptors","volume":"67","author":"Yoshida","year":"2005","journal-title":"Epilepsy Res"},{"key":"2026020304081986300_jvim17108-bib-0006","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0920-1211(97)00097-1","article-title":"The anticonvulsant zonisamide scavenges free radicals","volume":"30","author":"Mori","year":"1998","journal-title":"Epilepsy Res"},{"key":"2026020304081986300_jvim17108-bib-0007","first-page":"961","article-title":"Absorption, distribution and excretion of 3-(surfamoyl [14C]methyl)-1,2-benzisoxazole (AD-180) in rats, dogs and monkeys and of AD-810 in men","volume":"33","author":"Matsumoto","year":"1983","journal-title":"Arzneimittelforschung"},{"key":"2026020304081986300_jvim17108-bib-0008","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1365-2885.2008.00955.x","article-title":"Pharmacokinetics of zonisamide and drug interaction with phenobarbital in dogs","volume":"31","author":"Orito","year":"2008","journal-title":"J Vet Pharmacol Ther"},{"key":"2026020304081986300_jvim17108-bib-0009","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/j.1365-2885.2008.00993.x","article-title":"Disposition and safety of zonisamide after intravenous and oral single dose and oral multiple dosing in normal hound dogs","volume":"31","author":"Boothe","year":"2008","journal-title":"J Vet Pharmacol Ther"},{"key":"2026020304081986300_jvim17108-bib-0010","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jfms.2008.01.006","article-title":"Pharmacokinetics and toxicity of zonisamide in cats","volume":"10","author":"Hasegawa","year":"2008","journal-title":"J Feline Med Surg"},{"key":"2026020304081986300_jvim17108-bib-0011","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/j.1528-1157.1979.tb04846.x","article-title":"Relationships between plasma concentrations of diphenylhydantoin, phenobarbital, carbamazepine, and 3-sulfamoylmethyl-1,2-benzisoxazole (AD-810), a new anticonvulsant agent, and their anticonvulsant or neurotoxic effects in experimental animals","volume":"20","author":"Masuda","year":"1979","journal-title":"Epilepsia"},{"key":"2026020304081986300_jvim17108-bib-0012","first-page":"477","article-title":"3-Sulfamoylmethyl-1,2-benzisoxazole, a new type of anticonvulsant drug: pharmacological profile","volume":"30","author":"Masuda","year":"1980","journal-title":"Arzneimittelforschung"},{"key":"2026020304081986300_jvim17108-bib-0013","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/0272-0590(88)90158-3","article-title":"Chronic toxicity of the anticonvulsant zonisamide in beagle dogs","volume":"11","author":"Walker","year":"1988","journal-title":"Fundam Appl Toxicol"},{"key":"2026020304081986300_jvim17108-bib-0014","article-title":"Domestic materials: pharmacokinetic study of zonisamide in dogs","author":"Bussan Animal Health Co, Ltd","year":"2008"},{"key":"2026020304081986300_jvim17108-bib-0015","doi-asserted-by":"crossref","first-page":"285","DOI":"10.5326\/0400285","article-title":"Zonisamide therapy for refractory idiopathic epilepsy in dogs","volume":"40","author":"Dewey","year":"2004","journal-title":"J Am Anim Hosp Assoc"},{"key":"2026020304081986300_jvim17108-bib-0016","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1748-5827.2006.00290.x","article-title":"Prospective study of zonisamide therapy for refractory idiopathic epilepsy in dogs","volume":"48","author":"Klopmann","year":"2007","journal-title":"J Small Anim Pract"},{"key":"2026020304081986300_jvim17108-bib-0017","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1080\/00480169.2012.680855","article-title":"Zonisamide monotherapy for idiopathic epilepsy in dogs","volume":"60","author":"Chung","year":"2012","journal-title":"N Z Vet J"},{"key":"2026020304081986300_jvim17108-bib-0018","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/jvim.13841","article-title":"2015 ACVIM small animal consensus statement on seizure management in dogs","volume":"30","author":"Podell","year":"2016","journal-title":"J Vet Intern Med"},{"key":"2026020304081986300_jvim17108-bib-0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2460\/javma.22.10.0469","article-title":"Comparison of caregivers' assessments of clinical outcome in dogs with idiopathic epilepsy administered levetiracetam, zonisamide, or phenobarbital monotherapy","volume":"261","author":"Gristina","year":"2023","journal-title":"J Am Vet Med Assoc"},{"key":"2026020304081986300_jvim17108-bib-0020","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1292\/jvms.11-0164","article-title":"Possible drug-induced hepatopathy in a dog receiving zonisamide monotherapy for treatment of cryptogenic epilepsy","volume":"73","author":"Schwartz","year":"2011","journal-title":"J Vet Med Sci"},{"key":"2026020304081986300_jvim17108-bib-0021","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1111\/j.1939-1676.2011.00783.x","article-title":"Apparent acute idiosyncratic hepatic necrosis associated with zonisamide administration in a dog","volume":"25","author":"Miller","year":"2011","journal-title":"J Vet Intern Med"},{"key":"2026020304081986300_jvim17108-bib-0022","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1292\/jvms.20-0045","article-title":"Hepatocellular necrosis with prominent regenerative reactions in a zonisamide administrated dog","volume":"82","author":"Takami","year":"2020","journal-title":"J Vet Med Sci"},{"key":"2026020304081986300_jvim17108-bib-0023","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/vde.12237","article-title":"Erythema multiforme associated with zonisamide in a dog","volume":"26","author":"Ackermann","year":"2015","journal-title":"Vet Dermatol"},{"key":"2026020304081986300_jvim17108-bib-0024","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1111\/j.1939-1676.2011.00801.x","article-title":"Renal tubular acidosis associated with zonisamide therapy in a dog","volume":"25","author":"Cook","year":"2011","journal-title":"J Vet Intern Med"},{"key":"2026020304081986300_jvim17108-bib-0025","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1002\/vms3.905","article-title":"Distal renal tubular acidosis and lethargy associated with zonisamide treatment in a dog with idiopathic epilepsy","volume":"8","author":"Itoi","year":"2022","journal-title":"Vet Med Sci"},{"key":"2026020304081986300_jvim17108-bib-0026","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3389\/fvets.2021.763822","article-title":"Abnormal behavior episodes associated with zonisamide in three dogs: a case report","volume":"8","author":"Kanazono","year":"2021","journal-title":"Front Vet Sci"},{"key":"2026020304081986300_jvim17108-bib-0027","article-title":"Forestry and fisheries No. 75. Japan: the guidelines for good clinical practice (GCP) for the conduct of clinical trials of veterinary medical products in Japan [enacted in 1997, revised in 2022]","author":"Ordinance of the Ministry of Agriculture","year":"1997"},{"key":"2026020304081986300_jvim17108-bib-0028","article-title":"Handling of Affairs Related to the Law Concerning the Assurance of Quality, Efficacy, and Safety of Pharmaceuticals and Medical Devices. National Veterinary Assay Laboratory (NVAL) Notification No. 12-A-418, March 31","author":"Director General of National Veterinary Assay Laboratory Ministry of Agriculture, Forestry and Fisheries","year":"2000"},{"issue":"4","key":"2026020304081986300_jvim17108-bib-0029","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/s12917-015-0461-2","article-title":"International veterinary epilepsy task force consensus report on epilepsy definition, classification and terminology in companion animals","volume":"11","author":"Berendt","year":"2015","journal-title":"BMC Vet Res"},{"key":"2026020304081986300_jvim17108-bib-0030","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1365-2885.2009.01097.x","article-title":"Steady-state pharmacokinetics of zonisamide in plasma, whole blood, and erythrocytes in dogs","volume":"33","author":"Fukunaga","year":"2010","journal-title":"J Vet Pharmacol Therap"},{"key":"2026020304081986300_jvim17108-bib-0031","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/FTD.0000000000000546","article-title":"Therapeutic drug monitoring of antiepileptic drugs in epilepsy: a 2018 update","volume":"40","author":"Patsalos","year":"2018","journal-title":"Ther Drug Monit"},{"issue":"4","key":"2026020304081986300_jvim17108-bib-0032","first-page":"267","article-title":"Evidence against a significant implication of carbonic anhydrase inhibitory activity of zonisamide in its anticonvulsive effects","volume":"44","author":"Masuda","year":"1994","journal-title":"Arzneimittelforschung"},{"issue":"4","key":"2026020304081986300_jvim17108-bib-0033","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s12917-015-0465-y","article-title":"International veterinary epilepsy task force consensus proposal: outcome of therapeutic interventions in canine and feline epilepsy","volume":"11","author":"Potschka","year":"2015","journal-title":"BMC Vet Res"}],"container-title":["Journal of Veterinary Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/38\/4\/2228\/66662400\/jvim17108.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/38\/4\/2228\/66662400\/jvim17108.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T09:08:36Z","timestamp":1770109716000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jvim\/article\/38\/4\/2228\/8448552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,1]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7,1]]}},"URL":"https:\/\/doi.org\/10.1111\/jvim.17108","relation":{},"ISSN":["1939-1676"],"issn-type":[{"value":"1939-1676","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,7]]},"published":{"date-parts":[[2024,7,1]]},"assertion":[{"value":"2023-12-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}